BRAIN Biotechnology Research and Information Network AG represents core values of innovation, collaboration, and sustainable development in the biotechnology research and information sector. With a steadfast commitment to utilizing cutting-edge technology, BRAIN AG strives to revolutionize industries by harnessing the power of nature's vast biodiversity. By fostering strong partnerships and collaborations, BRAIN AG aims to provide novel solutions that address challenges in areas such as healthcare, nutrition, and consumer goods. With a focus on sustainability, BRAIN AG actively promotes environmentally friendly practices and the responsible use of resources. BRAIN AG's corporate philosophy revolves around unlocking the potential of nature and delivering value to its stakeholders through pioneering biotechnological research and information networks.

BRAIN Biotechnology Research and Information Network AG primarily operates in Germany and has a strong presence in Europe.

BRAIN Biotechnology Research and Information Network AG has achieved several significant milestones since its inception. The company has successfully established itself as a leading provider of innovative solutions in the field of biotechnology research and information. BRAIN AG has developed groundbreaking technologies and solutions that have revolutionized many industries, including pharmaceuticals, agriculture, and nutrition. The company's collaborative efforts with renowned partners have resulted in numerous successful research projects and product developments. Additionally, BRAIN AG has received prestigious recognition and awards for its outstanding contributions to the biotechnology sector. Overall, BRAIN Biotechnology Research and Information Network AG continues to make remarkable strides in advancing the boundaries of biotechnology innovation and research.

BRAIN Biotechnology Research and Information Network AG, commonly known as BRAIN AG, is a renowned company in the biotechnology sector. Established in 1993, BRAIN AG has a strong history of pioneering advancements in the field of industrial biotechnology. This German-based company specializes in the discovery and development of innovative bio-based products and solutions. With a focus on exploiting the vast potential of nature's biodiversity, BRAIN AG applies its unique BioArchive to identify novel enzymes, microorganisms, and natural substances for various industrial applications. Over the years, BRAIN AG has successfully collaborated with numerous industry partners, leading to groundbreaking innovations in areas such as agriculture, consumer goods, and pharmaceuticals. With its rich history and expertise, BRAIN AG continues to redefine the boundaries of biotechnological research and development.

The main competitors of BRAIN Biotechnology Research and Information Network AG in the market include companies such as BASF SE, Novozymes A/S, and Codexis, Inc. These companies are also involved in the biotechnology and research sectors, offering innovative solutions and products. However, BRAIN AG differentiates itself through its comprehensive portfolio of bio-based products, cutting-edge technologies, and expertise in biotechnology, strand synthesis, and enzyme engineering. This allows BRAIN AG to offer customized and sustainable solutions for various industries, including food and nutrition, pharmaceuticals, and cosmetics.

BRAIN Biotechnology Research and Information Network AG is primarily active in the biotechnology industry.

The business model of BRAIN Biotechnology Research and Information Network AG revolves around the development and commercialization of innovative solutions for the bio-based economy. BRAIN offers industrial partners access to a wide range of bioactive substances and enzymes derived from natural resources. The company utilizes its proprietary BioArchive and BioXtractor technologies to discover and optimize these valuable compounds. BRAIN then collaborates with various industries, including the chemical, pharmaceutical, and food sectors, to develop customized solutions for their specific needs. By leveraging its expertise in biotechnology and bioinformatics, BRAIN aims to contribute to sustainable and resource-efficient processes in industries worldwide.

Το BRAIN Biotech P/E είναι -159,39.

Το KUV της εταιρείας BRAIN Biotech είναι 1,07.

Το AlleAktien Qualitätsscore για το BRAIN Biotech είναι 4/10.

Ο κύκλος εργασιών του αναμενόμενη BRAIN Biotech είναι 65,47 Εκ. EUR.

Το αναμενόμενη BRAIN Biotech κέρδος είναι -441.369,98 EUR.

The BRAIN Biotechnology Research and Information Network AG specializes in the research and development of innovative biotechnological products. The company is divided into three different divisions: BioScience, BioIndustrial, and BioResources. The BioScience division focuses primarily on identifying and characterizing new active substances and enzymes from nature. BRAIN works closely with various global industrial companies to translate research findings into marketable products. The BioScience division is also responsible for conducting customized research projects tailored to the specific needs of the companies. BRAIN's BioIndustrial division focuses on the development and production of customized enzymes and microorganisms for industrial applications in various industries, such as food, paper, and textile. By using biotechnological processes, products can be produced in a more environmentally friendly manner and resources can be saved. BRAIN's BioResources division specializes in the use of biomass for the extraction of valuable raw materials. Sustainable and environmentally friendly methods are used to produce high-quality products such as bioenergy, biorefinery products, and biopolymers from biological waste and residues. BRAIN offers customers a comprehensive range of services in the field of biotechnological research and development. The company emphasizes a strong customer-oriented approach and close collaboration with industry partners. BRAIN has a large number of patents and market approvals that emphasize the high quality of its products. BRAIN's products include enzymes for the food industry for cheese and bread production, as well as specially adapted microorganisms for the production of bioethanol or biogas. In the cosmetics industry, BRAIN also offers innovative solutions such as natural active ingredients for skin and hair care products. In summary, BRAIN offers a wide range of biotechnological solutions for sustainable and efficient production in various industries. The close collaboration with industry partners allows for meeting individual customer needs and offering tailored solutions. BRAIN is an innovative company that is globally at the forefront of biotechnology due to its high level of research and development performance and the use of state-of-the-art technology. BRAIN specializes in the research and development of biotechnological products in various industries.

Η BRAIN Biotech καταβάλλει μια διανομή της τάξεως των 0 EUR διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το BRAIN Biotech αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της BRAIN Biotech είναι DE0005203947.

Το WKN της BRAIN Biotech είναι 520394.

Ο τίκερ της BRAIN Biotech είναι BNN.DE.

Κατά τους τελευταίους 12 μήνες η BRAIN Biotech κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η BRAIN Biotech προβλέπεται να πληρώσει μέρισμα 0 EUR.

Η απόδοση μερίσματος της BRAIN Biotech ανέρχεται σήμερα στο .

BRAIN Biotech πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η BRAIN Biotech πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 EUR. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το BRAIN Biotech ανατίθεται στον τομέα 'Βασικά Υλικά'.

Για να λάβεις το τελευταίο μέρισμα των BRAIN Biotech από την 29/1/2025 με τιμή 0 EUR, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 29/1/2025.

Η τελευταία μερίσματος έγινε στις 29/1/2025.

Το έτος 2024, η BRAIN Biotech διένειμε 0 EUR ως μερίσματα.

Τα μερίσματα του BRAIN Biotech καταβάλλονται σε EUR.